Spots Global Cancer Trial Database for smoldering multiple myeloma
Every month we try and update this database with for smoldering multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Denosumab for Smoldering Multiple Myeloma | NCT03839459 | Smoldering Mult... | Denosumab | 18 Years - | University of Rochester | |
| PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | NCT03850522 | Smoldering Mult... | PD-L1 peptide | 18 Years - | Herlev Hospital | |
| Screening for AL Amyloidosis in Smoldering Multiple Myeloma | NCT06365060 | Smoldering Mult... | 40 Years - | Tufts Medical Center | ||
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Screening to Improve Survival in AL Amyloidosis | NCT04615572 | Smoldering Mult... Monoclonal Gamm... | 60 Years - | Tufts Medical Center | ||
| Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | NCT04850846 | Monoclonal Gamm... Smoldering Mult... | Metformin XR Placebo | 18 Years - | Dana-Farber Cancer Institute | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | NCT05283993 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm... | No intervention | - | Peking University First Hospital | |
| A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) | NCT03815279 | Multiple Myelom... Smoldering Mult... | Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Landspitali University Hospital | |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders | NCT01177527 | Multiple Myelom... Waldenstrom's M... Smoldering Mult... Lymphoblastic L... | 18 Years - | Dana-Farber Cancer Institute | ||
| MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey | NCT04727294 | Multiple Myelom... Smoldering Mult... Monoclonal Gamm... Coronavirus | Questionnaire | 18 Years - | HealthTree Foundation | |
| Screening to Improve Survival in AL Amyloidosis | NCT04615572 | Smoldering Mult... Monoclonal Gamm... | 60 Years - | Tufts Medical Center | ||
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | NCT05283993 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm... | No intervention | - | Peking University First Hospital | |
| Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma | NCT00942422 | Multiple Myelom... Precancerous Co... | defined green t... gene expression... protein analysi... laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma | NCT01169337 | Light Chain Dep... Smoldering Mult... | Clinical Observ... Lenalidomide Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| The Indiana Myeloma Registry | NCT03616483 | Plasma Cell Dys... | This is a non-i... | 18 Years - | Indiana University | |
| A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma | NCT01219010 | Monoclonal Gamm... Multiple Myelom... Plasma Cell Neo... | Siltuximab | 18 Years - | Janssen Research & Development, LLC | |
| Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | NCT05597345 | Smoldering Mult... | Selinexor | 18 Years - | University of Rochester | |
| PROFAST Intervention in Precursor Multiple Myeloma | NCT05565638 | Cancer Preventi... Weight Loss Smoldering Wald... MGUS Fasting Multiple Myelom... | Prolonged Fasti... EDUCATION CONTR... | 18 Years - | Dana-Farber Cancer Institute | |
| Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | NCT04850846 | Monoclonal Gamm... Smoldering Mult... | Metformin XR Placebo | 18 Years - | Dana-Farber Cancer Institute | |
| Registry for Adults With Plasma Cell Disorders (PCD's) | NCT03717844 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | NCT04850846 | Monoclonal Gamm... Smoldering Mult... | Metformin XR Placebo | 18 Years - | Dana-Farber Cancer Institute | |
| Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients | NCT02943473 | High Risk Smold... | Ibrutinib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | NCT02269592 | Monoclonal Gamm... Chronic Lymphoc... Myelodysplastic... Hematological M... B-cell Malignan... Myelodysplastic... IgG Monoclonal ... Smoldering Mult... Waldenstrom Mac... | 18 Years - | Dana-Farber Cancer Institute | ||
| Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant | NCT03289299 | Smoldering Mult... | Carfilzomib Lenalidomide Daratumumab Dexamethasone | 18 Years - | International Myeloma Foundation | |
| Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma | NCT01718899 | Smoldering Mult... | PVX-410 | 18 Years - 95 Years | OncoPep, Inc. | |
| Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial | NCT06212323 | Smoldering Mult... | Patients with s... | 18 Years - | University of Utah | |
| Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | NCT02415413 | Smoldering Mult... | carfilzomib Lenalidomide Dexamethasone Melphalan | 18 Years - 70 Years | PETHEMA Foundation | |
| Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma | NCT01718899 | Smoldering Mult... | PVX-410 | 18 Years - 95 Years | OncoPep, Inc. | |
| Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma | NCT00942422 | Multiple Myelom... Precancerous Co... | defined green t... gene expression... protein analysi... laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | NCT00899353 | Monoclonal Gamm... Smoldering Mult... Chronic Lymphoc... | Omega 3 Fatty A... | 18 Years - | Marshall University | |
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma | NCT06183489 | Smoldering Mult... | Elranatamab | 18 Years - | Stichting European Myeloma Network | |
| E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma | NCT02279394 | Smoldering Myel... Smoldering Mult... | Elotuzumab Lenalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma | NCT01955395 | Monoclonal Gamm... Smoldering Mult... | Relaxation Resp... | 18 Years - | Massachusetts General Hospital | |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| A Phase II Study of BI-505 in Smoldering Multiple Myeloma | NCT01838369 | Smoldering Mult... | BI-505 | 18 Years - | BioInvent International AB | |
| A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | NCT02886065 | Smoldering Mult... | Hiltonol Citarinostat Lenalidomide PVX-410 | 18 Years - | Massachusetts General Hospital | |
| Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | NCT05469893 | High-risk Smold... Smoldering Mult... Multiple Myelom... | Teclistamab Lenalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma | NCT06183489 | Smoldering Mult... | Elranatamab | 18 Years - | Stichting European Myeloma Network | |
| A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) | NCT03815279 | Multiple Myelom... Smoldering Mult... | Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Landspitali University Hospital | |
| CAR- PRISM (PRecision Intervention Smoldering Myeloma) | NCT05767359 | Multiple Myelom... Smoldering Mult... | Ciltacabtagene ... Cyclophosphamid... Fludarabine Pho... | 18 Years - | Dana-Farber Cancer Institute | |
| Promoting Diagnosis and Management of AL in Italy (ProDigALIty) | NCT06383143 | AL Amyloidosis Smoldering Mult... Monoclonal Gamm... | no intervention | 18 Years - 99 Years | IRCCS Policlinico S. Matteo | |
| A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) | NCT04920084 | Monoclonal Gamm... Smoldering Mult... | Plant based mea... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Screening to Improve Survival in AL Amyloidosis | NCT04615572 | Smoldering Mult... Monoclonal Gamm... | 60 Years - | Tufts Medical Center | ||
| The Indiana Myeloma Registry | NCT03616483 | Plasma Cell Dys... | This is a non-i... | 18 Years - | Indiana University | |
| Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | NCT02415413 | Smoldering Mult... | carfilzomib Lenalidomide Dexamethasone Melphalan | 18 Years - 70 Years | PETHEMA Foundation | |
| Promoting Diagnosis and Management of AL in Italy (ProDigALIty) | NCT06383143 | AL Amyloidosis Smoldering Mult... Monoclonal Gamm... | no intervention | 18 Years - 99 Years | IRCCS Policlinico S. Matteo | |
| Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma | NCT00942422 | Multiple Myelom... Precancerous Co... | defined green t... gene expression... protein analysi... laboratory biom... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma | NCT03301220 | Smoldering Mult... | Daratumumab SC:... | 18 Years - | Janssen Research & Development, LLC | |
| Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial | NCT06212323 | Smoldering Mult... | Patients with s... | 18 Years - | University of Utah | |
| Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma | NCT00099047 | Monoclonal Gamm... Multiple Myelom... Smoldering Mult... | celecoxib placebo laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma | NCT01955395 | Monoclonal Gamm... Smoldering Mult... | Relaxation Resp... | 18 Years - | Massachusetts General Hospital | |
| Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program | NCT05831358 | Multiple Myelom... Monoclonal Gamm... Smoldering Mult... | Multiple Myelom... Multiple Myelom... | 50 Years - | Case Comprehensive Cancer Center | |
| Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma | NCT04850846 | Monoclonal Gamm... Smoldering Mult... | Metformin XR Placebo | 18 Years - | Dana-Farber Cancer Institute | |
| Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program | NCT05831358 | Multiple Myelom... Monoclonal Gamm... Smoldering Mult... | Multiple Myelom... Multiple Myelom... | 50 Years - | Case Comprehensive Cancer Center | |
| Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations. | NCT04144387 | Smoldering Mult... | Myelogram | 18 Years - | Intergroupe Francophone du Myelome | |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| European Myeloma Network (EMN) Sample Project | NCT06237803 | Multiple Myelom... Smoldering Mult... Plasma Cell Leu... Extramedullary ... MGUS | storage of biol... | 18 Years - | Stichting European Myeloma Network | |
| The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma | NCT05841550 | Multiple Myelom... Smoldering Mult... | TG01 | 18 Years - | Oslo University Hospital | |
| PROFAST Intervention in Precursor Multiple Myeloma | NCT05565638 | Cancer Preventi... Weight Loss Smoldering Wald... MGUS Fasting Multiple Myelom... | Prolonged Fasti... EDUCATION CONTR... | 18 Years - | Dana-Farber Cancer Institute | |
| Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma | NCT01441973 | Smoldering Mult... | Elotuzumab (BMS... | 18 Years - | Bristol-Myers Squibb | |
| European Myeloma Network (EMN) Sample Project | NCT06237803 | Multiple Myelom... Smoldering Mult... Plasma Cell Leu... Extramedullary ... MGUS | storage of biol... | 18 Years - | Stichting European Myeloma Network | |
| A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma | NCT02903381 | Smoldering Mult... | Nivolumab Lenalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma | NCT02916771 | Smoldering Mult... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute | |
| Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma | NCT03236428 | Monoclonal Gamm... Smoldering Mult... | Daratumumab | 18 Years - | Dana-Farber Cancer Institute | |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders | NCT01177527 | Multiple Myelom... Waldenstrom's M... Smoldering Mult... Lymphoblastic L... | 18 Years - | Dana-Farber Cancer Institute | ||
| PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | NCT03850522 | Smoldering Mult... | PD-L1 peptide | 18 Years - | Herlev Hospital | |
| CAR- PRISM (PRecision Intervention Smoldering Myeloma) | NCT05767359 | Multiple Myelom... Smoldering Mult... | Ciltacabtagene ... Cyclophosphamid... Fludarabine Pho... | 18 Years - | Dana-Farber Cancer Institute | |
| Registry for Adults With Plasma Cell Disorders (PCD's) | NCT03717844 | Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | NCT03850522 | Smoldering Mult... | PD-L1 peptide | 18 Years - | Herlev Hospital | |
| Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions | NCT05361694 | Multiple Myelom... Smoldering Mult... Monoclonal Gamm... | 18 Years - | University of Miami | ||
| Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | NCT00112827 | Refractory Mult... Smoldering Mult... Stage I Multipl... Stage II Multip... Stage III Multi... | total marrow ir... melphalan peripheral bloo... filgrastim fluorescence in... cytogenetic ana... cyclophosphamid... autologous-auto... lenalidomide | - 70 Years | City of Hope Medical Center | |
| A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma | NCT02903381 | Smoldering Mult... | Nivolumab Lenalidomide Dexamethasone | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
